Resolution of inflammation, an actively coordinated program, is essential to maintain host health. It involves effective removal of inflammatory stimuli and the spatio-temporal control of leukocyte trafficking as well as chemical mediator generation. During the active resolution process, new classes of small, local acting endogenous autacoids, namely the lipoxins, D and E series resolvins, (neuro)protectins, and maresins have been identified. These specialized pro-resolving lipid mediators (SPM) prevent excessive inflammation and promote removal of microbes and apoptotic cells, thereby expediting resolution and return to tissue homeostasis. As part of their molecular mechanism, SPM exert their potent actions via activating specific pro-resolving G-protein coupled receptors. Together these SPM and their receptors provide new concepts and opportunities for therapeutics, namely promoting active resolution as opposed to the conventionally used enzyme inhibitors and receptor antagonists. This approach may offer new targets suitable for drug design for treating inflammation related diseases, for the new terrain of resolution pharmacology.
Introduction
Many of the currently used anti-inflammatory therapies are directed towards the inhibition of enzymes and/or antagonism of pro-inflammatory receptors. Selective cyclooxygenase inhibitors and anti-tumor necrosis factor α (TNF-α) are examples of this approach to treatment. Research in the author's laboratory has focused on profiling self-limited inflammation, which uncovered novel mechanisms that terminate the local acute inflammatory response as well as stimulate resolution and return of the tissue to homeostasis [1, 2] . Identification of these biochemical and cellular processes indicate that resolution of acute inflammation, once considered a passive process, is an active programmed tissue process; reviewed in Refs. [3, 4] . Hence, rather than targeting inhibition or antagonism of inflammation, our research efforts address the potential use of endogenous agonists of resolution to stimulate naturally resolving inflammation.
This systems approach with self-limited exudates now opens a new understanding of the mechanisms underlying inflammatory disease as well as a new discipline, namely resolution pharmacology. Essential omega-3 fatty acids, in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are precursors to a new genus of potent lipid mediators (LM) that are both pro-resolving and anti-inflammatory (specialized pro-resolving mediators: SPM) and serve a physiologic role defining programmed resolution. This mini-review highlights the biosynthesis and actions of this novel genus of endogenous SPM that govern resolution of acute inflammation.
New Principles in Resolution -Endogenous Chemical Mediators of Resolution
The acute inflammatory reaction in response to infection or unwanted tissue damage is characterized by the classic cardinal signs of inflammation (heat, redness, swelling and pain), and in experimental settings in vivo the temporal relationships are well established, e.g., edema and the accumulation of leukocytes, specifically polymorphonuclear leukocytes (PMN), followed by monocytes and macrophages [5, 6] . These events in self-limited or resolving inflammatory reactions are coupled with release of local factors that prevent further or excessive trafficking of leukocytes allowing for resolution [1, 2] . Early in the inflammatory response, pro-inflammatory mediators such as prostaglandins and leukotrienes play an important role [7] . The progression from an acute to chronic inflammation as in many widely occurring human diseases such as arthritis, periodontal disease [8] and cardiovascular disease [9] is commonly viewed as an excess of pro-inflammatory mediators. Although mononuclear cells can sometimes contribute to pro-inflammatory responses, they are also critical in wound healing, tissue repair and remodeling in a non-phlogistic fashion [10] . Thus, it is highly plausible that defects associated with mounting endogenous proresolving circuits and local autacoids could underlie some of the pathologic events in chronic inflammation.
The complete resolution of an acute inflammatory response and the return of the local tissues to homeostasis is necessary for ongoing health. Removal of leukocytes from tissues involved in the inflammatory response without leaving remnants of the host defenses and combat between leukocytes, invading microbes, and/or other initiators of inflammation is an ideal outcome. We have focused on the question "How is the acute inflammatory response regulated?" since it was widely believed that simple dilution of pro-inflammatory mediators is sufficient to "burn out" inflammation, with the subsequent responses ending passively [5, 10] .
Pro-resolving Lipid Mediators and Anti-Inflammation
Lipoxins and aspirin-triggered lipid mediators SPM are a recently uncovered genus of endogenously biosynthesized chemical mediators identified in exudates and consists of four distinct new chemical families: lipoxins, resolvins, protectins and the recently identified maresins, which are involved in acute inflammation. Each of these families is actively biosynthesized in the resolution phase of acute inflammation and the mediators are potent agonists that control the duration and magnitude of inflammation [2, 11, 12] . They are also potent chemoattractants, but via a noninflammatory mechanism: for example, lipoxins from arachidonate activate mononuclear cell recruitment without stimulating release of pro-inflammatory chemokines or activation of pro-inflammatory gene pathways [3] . They also stimulate the uptake of apoptotic PMNs [13] and activate endogenous anti-microbial defense mechanisms [14] as well as clearance on mucosal surfaces [15] . These actions are agonistic in that they stimulate specific cell surface receptors; via acting on separate cell populations they stimulate overall resolution of inflammation.
Lipoxin A 4 (LXA 4 ) and LXB 4 , which are lipoxygenase derived eicosanoids, are antiinflammatory and were the first pro-resolving mediators identified, as their appearance signals the resolution of acute contained inflammation [16] . Lipoxins are derived enzymatically from arachidonic acid (AA), an omega-6 fatty acid that is released and mobilized during inflammation [7] . In human systems, they are biosynthesized, for example, during cell-cell interactions involving mucosal, i.e., epithelial cells of the gastrointestinal tract or bronchial tissue, interactions with leukocytes; within the vasculature plateletleukocyte interactions are a main source [3] . Aspirin has an unexpected impact within resolution as it "jump-starts" the process by triggering endogenous biosynthesis of proresolving lipid mediators [17, 18] .
During local contained inflammation, the first line of host defense, namely the neutrophils, die at the site and can undergo cell death by apoptosis as well as necrosis. As part of resolution, LX signal macrophages to enhance their uptake of the remains of these cells [13] . LX are highly potent anti-inflammatory mediators that are formed and act in picogram to nanogram amounts with human tissues and in animal disease models [16] . LX have the specific pro-resolution actions of limiting PMN recruitment and adhesion. They essentially serve as braking signals for PMN-mediated tissue injury. [see ref. 16 and references within].
Resolvins and protectins: Novel Chemical Mediators from Omega-3 Precursors
Resolvins and protectins are two distinct families of local mediators identified in the resolving exudates of acute inflammation. They were initially identified using a systems approach with LC-MS-MS-based lipidomics and informatics and then complete structural elucidation of the bioactive mediators and related compounds was achieved [1, 2, [18] [19] [20] . The term resolvins or resolution-phase interaction products refers to endogenous bioactive mediators biosynthesized from the major omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) namely the E series (RvE) and D series (RvD) resolvins [2] . Aspirin-triggered forms of resolvins are produced by a COX-2-dependent pathway in the presence of aspirin. A growing body of evidence indicates that resolvins possess potent anti-inflammatory and immunoregulatory actions that include blocking the production of pro-inflammatory mediators and regulating trafficking of leukocytes [reviewed in Ref. 4] . Specifically, resolvins stop PMN infiltration in vivo and transmigration [2, 21] . They also reduce cytokine expression by isolated microglia cells [19] . We also established the stereochemistry and actions of RvD1 and aspirin-triggered (AT)-RvD1, RvE1 and PD1 (vide infra) as well as demonstrated the stereoselective basis for their potent actions [18, 20, 21] . Both RvD1 and its 17R-AT form (0-1000 nM) stop PMN transendothelial migration in a concentration-dependent manner [21] . The potency of these compounds is noteworthy, with 50% reduction in PMN transmigration at 10 nM. RvD1 actions were studied in several inflammatory disease models and confirmed to be potent and stereoselective (Table 1) .
Protectins are also biosynthesized from DHA via a distinct pathway. Protectins are distinguished by the presence of their conjugated triene containing structure [20] . The name "protectins" was coined from the observed anti-inflammatory [19] and protective actions. The prefix neuroprotectin gives the tissue location of its production, such as neuroprotectin D1 [20, 22] . Like resolvins, the protectins also stop PMN infiltration [19, 20] . They are biosynthesized by and act on glial cells and reduce cytokine expression [19] . In mouse models, NPD1 reduces the severity of retinal and corneal injury [22] and stroke damage [23] , and improves wound healing in the cornea [24] .
Programmed Resolution of Inflammation
To study self-limited inflammation using an unbiased systems approach, the murine dorsal air pouch was ideal because it permitted isolation of contained inflammatory exudates [1, 2] . This system also enabled direct LM-lipidomics-informatics (bioactive products, as well as their inactive precursors and further metabolites), proteomics, and cellular composition of the resolving exudate. Importantly, it was possible to establish by direct comparisons when and where different local mediators were biosynthesized and activated for resolution, namely temporal spatial differential analyses [3, 25] . We used the murine dorsal air pouch as well as peritonitis to determine the formation and roles of endogenous LXA 4 in the resolution of acute inflammation [26] .
Upon initiation of inflammation with TNF-α, there was a typical acute-phase response characterized by rapid PMN infiltration preceded by generation of both local prostaglandins and leukotrienes. Unexpectedly, the eicosanoids then underwent what we termed earlier a "class switch." As the exudate evolved, the eicosanoid profiles switched and the lipid mediators made within this milieu changed with time [26] . Indeed, leukotrienes (potent chemo-attractants) were deactivated and the transcriptional regulation of enzymes required for LX and resolvin production was activated. Resolvin biosynthesis by exudates utilizes plasma edema to carry the omega-3 DHA and EPA for conversion by exudates [27] . This in turn chemoattracts mononuclear cells and stimulates macrophages to ingest apoptotic neutrophils within these contained inflammatory exudate site. Interestingly, the lipid mediator class switch in exudates was driven in part by COX-derived prostaglandins E 2 and D 2 , which regulate transcription of enzymes involved in lipoxin biosynthesis [26] . Along with Sir John Savill we introduced the concept that "alpha signals omega," namely the beginning signals the end in inflammation [10] .
DHA is well established to play an important role in neuronal systems and, along with AA, is also one of the major polyunsaturated fatty acid (PUFA) component found in the retina. The other major omega-3 PUFA present in marine fish oils is EPA. In order to determine whether EPA, DHA, and AA regulate inflammation in vivo, we studied disease models to compare the effects of omega-3 and -6 PUFAs in wild-type mice with mice that overexpress the C. elegans fat-1 gene. This gene converts omega-6 PUFA into omega-3 resulting in elevated tissue levels of omega-3 PUFA within the fat-1 overexpressing mice. A protective action against pathological angiogenesis was found in retina when there was a lower ratio of omega-6:omega-3 PUFA [28] . Wild-type mice lacking the fat-1 transgene had extensive vaso-obliteration and severe retinal neovascularization compared with fat-1 mice. In mice fed omega-3 PUFA, there were markers of neuroprotectin D1 (NPD1) and RvE1 biosynthesis. In mice without omega-3 PUFA supplementation, administration of RvD1, RvE1, or NPD1 gave protection from vaso-obliteration and neovascularization [28] . These fat-1 mice are also protected from colitis [29] . In addition to exudates, murine bone marrow also synthesizes resolvins and protectins, which are enhanced with feeding EPA and DHA [30] SPM play a protective role in peritonitis. For example, zymosan A was injected into mice to initiate peritonitis [20] and PD1 was protective [20, 21, 25] . RvE1 and PD1 each blocked >85% of further PMN migration into the site [20] . When both PD1 and RvE1 were injected together to determine whether their actions were synergistic or additive, RvE1 (10 ng) reduced PMN infiltration, although less than that with PD1 (10 ng). In combination, the reduction was greater, suggesting an additive action. Along these lines, inflammatory bowel disorders, like colitis, are characterized by relapsing inflammation. In a well-studied experimental colitis model, RvE1 protects against bowel inflammation in mice challenged with an intrarectal antigenic hapten, 2,4,6-trinitrobenzene sulfonic acid (TNBS), to induce colitis [31] . As little as 1 μg RvE1 dramatically reduced mortality, weight loss, and histologic severity of colitis. Finally, RvE1 is protective in rabbit periodontal disease, where it appears to stimulate regeneration [32] . These findings exemplify the anti-inflammatory and anti-fibrotic actions of SPM in several widely used laboratory disease models (see Table  1 ). LXA 4 is an endogenous lipid mediator thatdisplays multi-level control of processes relevant in acute inflammation via specific and selective actions demonstrated for several isolated cell types and by interaction with specific receptors [3] . These receptors and sites of LX action were recently subject to review and respond to LXA 4 depending on its tissue and location of formation [see ref. 33 for detailed review]. LXA 4 directly interacts, for example, with human FPRL1 (ALX/FPR2) and cysLT1, as well as signals to regulate BLT1, cytokinechemokine receptors (e.g. TNF) and growth factor receptors (i.e., VEGF) in human leukocytes, vascular cells and mucosal epithelial cells, each contributing to regulate the resolution of inflammation [16] . In nanogram amounts, LXA 4 stops PMN infiltration in vivo [38, 39] and blocks human PMN transmigration across mucosal epithelial cells and vascular endothelial cells [40, 41] . In general terms, it is now well appreciated that LXA 4 actively "turns down" many endogenous processes that can amplify local acute inflammation; these include regulating leukocyte infiltration, TNF-stimulated cytokine and chemokine production, expression of chemokine receptors, adhesion molecules and production of reactive oxygen species as well as leukotriene formation and their actions [reviewed in refs. 3, 33] . To address the mechanism and sites of action for LXA 4 , radiolabeled [11, H]-LXA 4 was synthesized almost twenty years ago from a synthetic [11, 12] -acetylenic precursor Fig. (1A) . Selective reduction of the carbon 11-12 positioned triple bond in an atmosphere enriched with 3 H gas and Lindlar catalyst gave labeled [11, H]-LXA 4 , which we isolated by reverse phase HPLC and separated from isomerization products as well as unwanted reaction products that included excess reduced species of thefour conjugated double bond system in LXA 4 . The RP-HPLC isolation of labeled [11, H]-LXA 4 was carried out routinely before each binding experiment and characterized using reported physical properties of the labeled LXA 4 . This qualification of the [ 3 H]-LXA 4 was critical for confident analyses and interpretation of isolated cell-based binding experiments [42] . Using freshly isolated [ 3 H]-LXA 4 for each experiment, specific LXA 4 binding sites were first identified in isolated human PMN [43] and provided a mechanistic basis for the specific LXA 4 functions and stimulated actions with PMN. Intact human PMN give specific [11, H]-LXA 4 binding at Kd=0.7 nM that was also found to be inducible in the promyelocytic lineage (HL-60) cells differentiated with either retinoic acid or dimethylsulfoxide (DMSO). LXA 4 stimulates rapid (within seconds) phospholipase activation in these cells that directly correlates with the induction time course of specific LXA 4 binding [44, 45] . In parallel experiments, a second approach was undertaken with GPCR that were known to be induced within the same time frame, namely 3 to 5 days. These receptors were screened for both [ 3 H]-LXA 4 binding and functional activation, namely ligand-receptor dependent increases in GTPase activity. High affinity specific [ 3 H]-LXA 4 binding was observed with one of the GPCR cloned earlier [46] from myeloid lineages, namely FPRL1; now renamed FPR2 [47] . When the action and ligands involve lipoxin A 4 or its mimetics/analogs, the receptor is denoted ALX/FPR2; for peptide agonists alone, FPR2 is proposed [47] .
Pro-Resolving GPCRs
Labeled LXA 4 binding with ALX/FPR2 has high affinity and selectivity compared to other eicosanoid heteroligands including lipoxin B 4 , leukotriene B 4 , leukotriene D 4 and PGE 2 . The plasmid DNA of this orphan receptor (denoted pINF114) at that time was transfected into Chinese Hamster Ovary (CHO) cells and gave a Kd ~1.7 nM for [ 3 H]-LXA 4 determined by Scatchard plot analysis [48] . This Kd value for recombinant human FPR2 is comparable to those obtained with the endogenous LXA 4 specific binding sites present on peripheral blood leukocytes. The human PMN has a remarkable Kd = 0.7 and 0.8 nM obtained with isolated plasma membrane fractions as well as granule membrane-enriched fractions. In addition, hFPR2-transfected CHO cells give functional responses with LXA 4 . This proved to be very useful in verifying that binding indeed conferred with cellular functions. In CHO cells expressing the recombinant receptor, LXA 4 stimulates both GTPase activity as well as the release of esterified arachidonic acid, which are inhibited by pertussis toxin. These agonist actions of LX obtained in vitro are in line with the anti-inflammatory properties of endogenous LXA 4 .
Human ALX/FPR2 was subsequently identified and cloned in several leukocyte subpopulations including monocytes [49] , T cells [50] , and macrophages as well as resident cells such as synovial fibroblasts [51] and intestinal epithelial cells [52] . Northern blot analysis demonstrated that the human ALX mRNA is ~2.1 Kb [39] , and chromosome mapping reveals that the gene encoding human ALX is located on chromosome 19q [53] . These reconstituted LXA 4 functional responses linked with specific LXA 4 binding and assignment of these functional ligand-receptor pairs (LXA 4 -ALX) [48] . This systematic screening of orphan receptors employed above takes into account both function and specific binding of receptors that are induced during myeloid cell differentiation. This was also the first identification of high affinity receptors for lipoxygenase pathway generated mediators.
Structure-activity relationships have been carried out at the level of both the ligand LXA 4 and the receptor ALX/FPR2. Each of the actions of LXA 4 proved to be stereoselective in that changes in potencies are associated with double bond isomerization and alcohol chirality (R or S) as well as dehydrogenation of alcohols and reduction of double bonds. Elimination of the carbon 15 position alcohol from LXA 4 , denoted 15-deoxy-LXA 4 , is essentially inactive in vivo and does not stop either PMN transmigration or reduce adhesion [54] . LXA 4 is enzymatically inactivated by conversion to 15-oxo-LXA 4 and 13, 14-dihydro-LXA 4 [55] . These further LXA 4 metabolites are essentially biologically inactive in stopping PMN transmigration and functional responses that are the key features of LXA 4 actions [56] . These pharmacophores for the anti-inflammatory action of the ligand LXA 4 , namely the carbon 15-hydroxyl group and 13, 14-double bond, are also required for their interaction with specific cell surface receptors. The biologically inactive metabolic products and synthetic compounds tested, including 15-oxo-LXA 4 , 15-deoxy-LXA 4 , 11-trans-LXA 4 and 13, 14-dihydro-LXA 4 , do not effectively bind to ALX/FPR2. This contrasts with the active LX ligands that include native LXA 4 , which carries a 15S-configuration alcohol that originates from the lipoxygenase biosynthetic pathway and the aspirin triggered 15R-or 15-epi-LXA 4 (also denoted ATL or aspirin-triggered LXA 4 ) biosynthesized in the presence of aspirin [3, 16] ; each exhibits stereospecific receptor binding to both the human and murine ALX/FPR2 [39] . Of interest, the carboxy-methyl ester of LXA 4 is a partial ALX/FPR2 antagonist and does not effectively regulate NF-κB activity [57] . The LXA 4 methyl ester also blocks PMN transmigration across both epithelial and endothelial cells, but is less potent in reducing PMN chemotaxis with isolated cells. This highlights the point that LXA 4 methyl ester is rapidly hydrolyzed to its corresponding free acid in vivo and/or in the presence of PMN and other cell types such as epithelial cells that possess the esterase activity. Thus, the pharmacologic additions of LXA 4 and/or LX analogs as carboxy methyl esters are pro-ligands or pro-drugs that require local conversion to their corresponding carboxylic acids to stimulate ALX/FPR2-mediated bioactions including intracellular, phosphorylation and gene regulation.
Since rhodopsin structure is more complete than our understanding of GPCR such as ALX/ FPR2 and its ligand interactions, it is instructive to compare the retinal chromophore of rhodopsin to fMLP and ligands. In this regard, 3-D modeling of the dimensions and spatial volumes for retinal, fMLP and LXA 4 have shown that they are remarkably similar in the 3-D spatial volumes [58] . Hence, similarities among the 3-D spatial volumes of ligands should reflect complementary sites in respective receptors as well as illustrate the spatial 3-D similarities among peptide vs. non-peptide or even lipid mediator ligands that might otherwise not seem obvious from their chemical structures.
The first ALX/FPR2 agonist identified for was micromolar fMLF [46] . The mouse ALX/ FPR cDNA was cloned from a spleen cDNA library [39] and, when expressed in CHO cells, gave specific [ 3 H]-LXA 4 binding, Kd=1.5 nM determined by Scatchard plot analysis and LXA 4 -initiated GTPase activity. Northern blot analysis showed that the mouse ALX mRNA is ~1. 4 Kb. An orthologue of ALX was also isolated from rat leukocyte which displayed both specific radioligand binding and LXA 4 -dependent inhibition of TNF-α mediated NF-κB activity [59] .
Human [48] , mouse [39] and rat [59] ALX/FPR2 cDNA all are characterized by an open reading frame of 1053 nucleotides which encodes a protein products that consists of 351 amino acids. To evaluate the structural contributions of the major domains from the receptor side via interactions with LXA 4 or anti-inflammatory and proinflammatory peptide ligands, chimeric receptors were constructed from ALX/FPR2 and BLT 1 receptors with opposing functions. These chimeras demonstrated that the seventh transmembrane and adjacent regions of the receptor are essential for LXA 4 recognition (see below), and additional regions including extracellular loops are required for high affinity binding for peptide ligands such as the MMK-1 and MHC peptides. A single GPCR can recognize and function with specific chemotactic peptides as well as non-peptide ligands such as LXA 4 . But, clearly, these ligands act with different affinities and/or at separate interaction sites within the receptor [60] . Of interest, conserved N-glycosylation sites are present on Asn-4 and Asn-179 of the human receptor, and bacterial and viral infection are known to interfere with normal N-glycosylation of the host cells [61] [62] [63] . In this regard, deglycosylation of ALX does not dramatically alter LXA 4 recognition, but significantly lowers the affinity for peptide ligands [60] . Thus, N-glycosylation is an essential post-translational modification for ligand specificity of this receptor and may play a pivotal role in switching or changing this receptor's functional attributes at local host defense sites.
Several conserved motifs and amino acid residues important for post-translational modification have been identified in this receptor. These residues are Ser-236, Ser-237 and Tyr-302, which are essential for human ALX phosphorylation and signaling. Site-directed mutagenesis of these residues and expression of the wild-type and mutated receptors in CHO and HL-60 cells demonstrated that mutation of ALX at either serine Ser-236 and 237 or tyrosine Tyr-302 phosphorylation sites gives sustained activation of both phospholipases PLA 2 and PLD. This contrasts with the transient activation of the wild-type receptor [64] . These structure-function studies (i.e. receptor chimera, glycosylation and phosphorylation) not only identify the key domains/residues important for ligand recognition and downstream signaling, but also further substantiate that LXA 4 is the highly stereospecific ligand for this receptor.
In addition to reports of anti-inflammatory ligands such as the annexin derived peptides that act at this and related receptors [65, 66] , another compelling line of evidence comes from mice transgenic for the human (ALX/FPR2) receptor [67] [68] [69] and isolated cell types overexpressing this receptor that signal to down-regulate epithelial IL-8 expression and inflammation [41] . The overexpression of the human receptor in mice leukocytes demonstrates a gain-of-function in phenotype with three different transgenic lines. Each of the transgenics overexpressing this receptor showed lower amplitude of acute inflammation and a response of considerably shorter duration. Thus, mice overexpressing this receptor showed quicker resolution times of inflammation and a heightened sensitivity to the antiinflammatory actions of a metabolically stable ligand, the ATL analog, in vivo compared to nontransgenic littermates. This higher potency displayed by the ATL mimetic in transgenic mice provides evidence for both an anti-inflammatory-pro-resolving role of this receptor in vivo as well as evidence for in vivo agonist LXA 4 ligand-receptor interactions.
Another independent line of investigation comes with the medicinal chemistry screening for human ALX/FPR2 agonists that identified non-peptide agonists with potent antiinflammatory actions i.e. blocking human PMN chemotaxis in vitro and oral administration in mice reducing inflammation in vivo [70, 71] . The formation and endogenous counterregulatory actions of LXA 4 and its interactions with ALX/FPR have expanded in recent years to include reduced pain signaling and the presence of the receptor in neural tissues [72] , a role in mucosal epithelial-based host-defense mechanisms with enhanced microbial killing [14] , expedited ocular wound healing [73] and ocular edema [74] . Lowdose aspirin induces ALX expression in humans and triggers 15-epi-LXA 4 formation, which regulates neutrophil entry in vivo [75] .
The intracellular signaling mechanisms sharply constrasts between peptide versus LXA 4 with ALX/FPR2. For example, fMLP relies heavily on Ca 2+ mobilization for its amplification via this receptor, while LXA 4 signaling attenuates nuclear factor-κB (NF-κB) activation and blocks phosphorylation of p38 ERK and c-Jun N-terminal kinase (JNK) [50, 72, 76] . Also, low doses of LXA 4 in vivo enhance the expression of the receptor, suggesting a positive feed-forward loop in the physiology of this receptor and its responses to local lipid mediator ligands such as LXA 4 [77] . The ligand-dependent intracellular signal of this receptor is cell-type dependent [3, 49] and fascinating [33, 47] , and warrants further studies to better understand the flexible and versatile ability of this receptor and its multiple liganddependent states of activation as well as its functional significance in human health and disease.
In order to determine the contributions of the major structural domains of ALX in interacting with either lipid or peptide ligands, chimeric receptors were constructed from receptors with opposing functions, namely ALX and BLT1. These chimeras reveal that the seventh transmembrane (TM) and adjacent regions of ALX are essential for LXA4 recognition, while additional regions of ALX (e.g. extracellular loops) are required for high affinity binding of selective peptide ligands (i.e. MMK-1 surrogate peptide and MHC binding peptide). These findings are the first to demonstrate that a single GPCR can recognize and function with specific peptides as well as lipid-derived ligands, LXA4. However these distinct classes of ligands (peptide vs. lipid-derived) clearly act with different affinities and/or interaction sites within the receptor, ALX. Moreover, one of the ALX-BLT1 chimera encompassing the third extracellular loop and the seventh TM domain of ALX retains the specific binding to LXA4 but not LTB4 [60] . More recently, Damian et al produced heterodimers of this chimera and the wild type BLT1 to investigate GPCR transactivation. Interestingly, ligand binding to one protomer in the heterodimer can induce cross-conformational changes in the other. However, these conformational changes are not associated with G protein trans-activation, i.e. agonist binding to one protomer cannot activate G proteins that are associated with the agonist-free protomer [78] .
RvE1 GPCR Interactions
RvE1 generation in vivo in humans-RvE1 was originally found in vivo during resolution phase of inflammation in exudates from murine dorsal pouches treated with aspirin and EPA, and was generated during co-incubation of human endothelial cells and neutrophils [1] . RvE1 was monitored using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in healthy human volunteers given EPA and aspirin [18] . The plasma values ranged from 0.1 to 0.4 ng/ml for 6 healthy subjects. The formation of RvE1 is consistent with the scheme that endothelial cells expressing COX-2 treated with aspirin transform vascular EPA to produce and release 18R-HEPE [1] . One route of RvE1 biosynthesis can be evoked in vivo. Human leukocyte and endothelial cell interaction within the vasculature, rapidly converts 18R-HEPE to RvE1 via transcellular biosynthesis [18] .
Identification of pro-resolving receptor candidates-The murine dorsal air pouch is a widely used experimental model to assess dermal inflammation [79] ; it is anatomically characterized by a cavity and a lining composed of both fibroblast-like and macrophage-like cells [79] . Intrapouch application of TNF-α evokes leukocyte infiltration by stimulating local release of chemokines and chemoattractants that are often produced by fibroblasts and phagocytes via regulation of nuclear factor (NF)-κB transcription factors [80] . The systemic administration of RvE1 dramatically attenuated leukocyte recruitment, suggesting the receptor target for RvE1 was expressed in those cells, which counterregulate TNF-α induced NF-κB activation. RvE1 and LXA 4 have different structures [see Fig. (1) ], are formed via different biosynthetic pathways and precursors (EPA vs arachidonate), yet they appear to share redundant beneficial actions that dampen excessive leukocyte recruitment [81] in the inflammatory milieu. Hence we reasoned that RvE1 receptors might share similar structural features to LOX-derived eicosanoid receptors such as ALX/FPR2 and the leukotriene (LT)B 4 receptor (BLT) [82] . Fig. (2A) (inset) illustrates a branch of the phylogenetic tree of G-protein coupled receptors (GPCRs) focused on human ALX/FPR2 with closely related receptors. Expression plasmids of each GPCR were introduced into HEK293 cells and the ability of RvE1 to inhibit TNF-α stimulated NF-κB activation was monitored by co-transfection with NF-κB response element-luciferase reporter plasmid. This permitted an unbiased analysis of the activation of the relevant post ligand-receptor "stop" signaling for downregulation of NF-κB activation as for example demonstrated with ALX-transfected cells and its ligands [83] . Among those screened [18] , the orphan receptor denoted earlier as ChemR23 [84] was specifically activated by RvE1 and at 10 nM inhibited NF-κB activation, as shown in Fig. (2A) . ChemR23 shares 36.4% identity with ALX in deduced amino acid sequences. Of note it contains a highly conserved domain in its second intracellular loop with 75% identity and within the seventh transmembrane region (69.5% identity with the corresponding regions in ALX).
RvE1 dose-dependently inhibited TNF-α induced NF-κB activation with an EC 50 of ~1.0 nM in ChemR23 transfected cells compared to mock [see Fig. (2B) ]. In this system, 1 mM aspirin, a known inhibitor of NF-κB at high concentrations namely millimolar range [85] , gave non-receptor dependent inhibition of 26.2±4.9% for the transfected cells. As shown in Fig. (2C) , neither EPA nor 18R-HEPE at 100 nM, both metabolic precursors of RvE1, inhibited NF-κB in ChemR23 transfected cells. The double bond isomer of RvE1, 6-trans, 14-trans-RvE1, at 100 nM showed reduced potency for NF-κB inhibition that was essentially the same magnitude reduction in vivo. We also examined functional interactions between ChemR23 and G proteins using ligand-dependent binding of [ 35 Radioligand Binding-RvE1 binding to ChemR23 was assessed with tritium-labeled RvE1, Fig. (1B) , which was prepared by catalytic hydrogenation from synthetic diacetylenic RvE1. Integrity of the synthetic [ 3 H]-RvE1 was confirmed by HPLC; radioactive compound co-eluted with synthetic RvE1 beneath a single peak in HPLC. Its characteristic UV absorbance maxima at 271 nm and 234 nm were indicative of the conjugated triene and diene in RvE1 structure. Analysis of [ 3 H]-labeled RvE1 specific binding and Scatchard transformation is shown in Fig. (3) . [ 3 H]RvE1 bound to an apparent single site on ChemR23 transfectants with high affinity (Kd=11.3±5.4 nM, Bmax=4200±1050 binding sites per cell). RvE1 biosynthesis precursors, EPA and 18R-HEPE, did not compete for specific [ 3 H]RvE1 binding. We also tested the synthetic peptide fragment (YHSFFFPGQFAFS) derived from chemerin that was recently reported to be a peptide ligand for this same receptor [86] . Chemerin peptide at 10 μM displaced specific [ 3 H]-RvE1 binding by ~70%, suggesting that RvE1 and chemerin share recognition sites on the same receptor ChemR23.
Expression, regulation and signaling properties of ChemR23-Profiling for tissue distribution of human ChemR23 was performed with dot blots containing mRNAs from human tissues that showed expression of ChemR23 such as cardiovascular system, brain, kidney, gastrointestinal tissues and myeloid tissues Fig. (4A) . Also, a murine receptor counterpart was found in developing bone using in situ hybridization [87] . Among the human peripheral blood leukocytes, ChemR23 was abundantly expressed in monocytes, with lower amounts in neutrophils and T lymphocytes, findings consistent with the observation that this receptor is expressed in antigen-presenting cells (APC) such as macrophage and dendritic cells (DCs) [84, 86] . Both monocyte ChemR23 and COX-2 transcripts were highly upregulated by treatment with inflammatory cytokines such as TNF-α and IFN-γ, and ChemR23 showed delayed induction to that of COX-2. RvE1 increased phosphorylation of extracellular signal-regulated kinase (ERK) mitogen-activated protein (MAP) kinase both in peripheral blood monocytes and HEK-ChemR23 cells, but not in mock-transfected HEK293 cells. In addition, treatment of HEK-ChemR23 with pertussis toxin (PTX) abolished RvE1 dependent ERK activation and NF-κB inhibition, suggesting that the receptor couples to the G-proteins of Gαi/o class for the signal transduction [18] .
Since RvE1 and chemerin peptide competed at the same receptor, it was of interest to determine whether there was a divergence between the responses initiated by these ligands. Chemerin-derived peptide activated ChemR23 as monitored by microphysiometry, evoking a response consistent with receptor-initiated increases in extracellular acidification rates (EAR) [18] . These results are in line with the reported properties of this peptide ligand [86] . RvE1 did not increase the EAR but selectively blocked the peptide-evoked responses. Consistently, the extent of G-protein activation evoked by chemerin peptide was 3 times as much as RvE1 whereas RvE1 was an order of magnitude more potent than chemerin peptide for inhibiting NF-κB activation. Thus, RvE1 interacts with ChemR23 and transmits signals via this receptor in a manner different than that of the chemerin-derived peptide.
RvE1-ChemR23 interaction blocks DC responses-Given expression of ChemR23
in antigen presenting cells (APCs), and since dietary ω-3 PUFA supplementation has an impact on APC function [88] , we examined the activity of RvE1 on APC function using a microbial pathogen model. Injection of pathogen extract derived from Toxoplasma gondii (STAg) causes activation of splenic DCs to mobilize to T cell enriched areas where they produce high amounts of IL-12 [89] . Addition of increasing concentrations of RvE1 to isolated mouse splenic CD11c + DCs markedly inhibited IL-12p40 production by STAg within the nanomolar range [18] . We next carried out siRNA experiments to reduce ChemR23 in splenic DCs. Mouse receptor [87] , which shares 80.3% identity with human ChemR23, was also present in splenic DCs. RvE1's action in regulating IL-12 production from DCs was eliminated by treatment with a siRNA specific for the mouse ChemR23. We confirmed that this siRNA treatment dramatically reduced ChemR23 mRNA expression in DCs and cell-surface expression of recombinant ChemR23 in HEK293 cells. Thus, RvE1's anti-inflammatory action is mediated via interaction with ChemR23. In vivo administration of RvE1 also blocked IL-12 production as well as DC migration into T cell areas of the spleen. RvE1 selectively interacts with BLT1-To examine whether the binding of RvE1 to BLT1 transduces intracellular signaling responses, we determined adenylyl cyclase activity by measuring the cAMP accumulation. LTB 4 inhibited 5 μM forskolin-activated adenylate cyclase activities in HEK-hBLT1 cells with EC 50 of 0.015 nM, a value consistent with that reported previously [82] . In these experiments, RvE1 inhibited adenylate cyclase activities with EC 50 of 3.2 nM. On the other hand, RvE1 gave no response with HEK-hBLT2 cells where LTB 4 gave signals (EC 50 =11.5 nM), a value consistent with the previous report [90] . These results indicate that RvE1 selectively binds and activates BLT1 to modulate intracellular signaling pathways.
Specific Binding of [ 3 H]-RvE1 with Human PMN-[
Arita et al. [91] reports the increase in intracellular calcium mobilization stimulated by LTB 4 or RvE1 in human PBMC. RvE1 at 100 nM increased intracellular calcium, but the maximum intensity of signal was only about one-third that of LTB 4 . Importantly, prior exposure to RvE1 completely blocked LTB 4 -induced intracellular Ca 2 response in a concentration dependent manner. Thus, RvE1 acts as a partial agonist to attenuate LTB 4 induced calcium signals in leukocytes.
Since LTB 4 induces pro-inflammatory cytokine and chemokine gene expression by activating the trancription factor, NF-κB [92] , we next determined whether RvE1 could modulate LTB 4 -BLT1 interaction induced NF-κB activation by using a luciferase reporter gene system. LTB 4 induced NF-κB activation in HeLa cells transfected with human BLT1 with EC 50 of 0.36 nM. This induction was almost completely abolished by 100 ng/ml pertussis toxin (PTX), suggesting that BLT1 coupled to PTX sensitive G-proteins such as Gi/o to activate NF-κB transcription factor. RvE1 concentrations above 100 nM gave partial activations of NF-κB that were in a range comparable to that of the BLT1 antagonist U-75302. Importantly, LTB 4 -dependent NF-κB activation was blocked by ~40-50% with RvE1 as low as 1 nM, which is an approximately 10-fold molar excess of LTB 4 . These results clearly demonstrated that RvE1 upon interaction with BLT1 attenuates LTB 4 -induced pro-inflammatory signals in a non-phlogistic manner.
BLT1-deficient mice and RvE1-We examined the functional outcome of RvE1-BLT1 interaction in vivo role in regulating leukocyte infiltration in zymosan A-induced peritonitis. In this model, zymosan activates resident macrophages and/or early accumulating neutrophils to produce LTB 4 from arachidonic acid, resulting in PMN influx in an autocrine loop of PMN accumulation during acute inflammation [93] . Intravenous administration of RvE1 at 100 ng dramatically blocked PMN infiltration by 38% at 2 h after zymosan injection in wild type mice. In contrast, RvE1 at 100 ng did not give statistically significant reduction in mice with targeted disruption of BLT1 (BLT1−/−). The early reduction of PMN influx in BLT1−/− mice, which represents BLT1-dependent PMN infiltrations, was noted as reported previously [93] . RvE1 reduced the numbers of infiltrating PMN in wild type mice to the levels of that obtained in BLT1−/− mice, indicating that intravenous administration of RvE1 at 100 ng blocked PMN migration by dampening BLT1 functions in vivo. Of interest, RvE1 at higher doses (1.0 μg i.v.) retained most of its anti-migratory actions in BLT1−/− mice, giving around 35% inhibition of PMN infiltration in both wild type and BLT1−/− mice. Together, these results demonstrate that intravenously administered RvE1 acts interacts with BLT1 and dampens BLT1 signals on leukocytes in addition to BLT1-independent mechanisms involving additional receptor(s) in vivo.
RvD1 Actions and its GPCRs
Single-cell (PMN) real-time monitoring: Direct Action of RvD1 and not DHAThe original structure elucidation of RvD1 demonstrated its presence and potent antiinflammatory actions in self-resolving exudates and disease models [2, 21] . We questioned whether RvD1 or its precursor DHA has direct actions with human PMN. This is a central point because excessive PMN infiltration with a release of pro-inflammatory mediators is well appreciated in causing tissue damage.
To address this question, we used a new microfluidic chamber (MFC) in collaboration with Drs. Irimia and Toner [27] . This chamber permits PMN capture in < 5 minutes within 1 cubic μl from 1 drop of whole blood from a finger prick (upper photo). Microstructured valves within the chamber controls the timing of exposing PMN to chemotactic gradients. Images of human PMN before and during exposure to gradients are continuously monitored using a camera and recorded. PMN chemotaxing along IL-8 gradients show typical shape change and morphology during chemotaxis in a linear gradient. Before exposure to RvD1, individual PMN movements and distances were proportional to time. Uniform exposure to RvD1 [10 nM] rapidly and dramatically changed PMN shape and ceased chemotaxis demonstrating stopping of PMN migration. In contrast, its precursor DHA at equimolar concentrations did not stop PMN [27] . Thus, RvD1 stops PMN as well as stimulates shape change.
Resolvins are tissue protective-Ischemia followed by reperfusion is a wellrecognized mechanism of organ injury and tissue damage that can be initiated by activated PMN. We studied murine hind-limb ischemia/reperfusion that models second organ injury and PMN mediated tissue damage observed in humans, for example, following tourniquet release of vessels in surgery involving extremities [5, 94] . On release of tourniquet occlusion, reflow is initiated and aberrantly activated PMN rapidly infiltrate murine secondary organs, causing damage [95] . We evaluated RvD1 in this system, to assess whether its ability to stop PMN in MFC could translate to reduction in PMN-mediated tissue damage. PMN accumulation in the lung was assessed by monitoring both tissue histology and a leukocyte marker myeloperoxidase [95] . Again, we directly compared actions of RvD1, DHA and RvE1. Neither native RvE1 nor DHA protected tissues from excessive PMN infiltration following reperfusion injury [27] , whereas at 1 μg/mouse RvD1 sharply reduced ~50% leukocyte infiltration.
Since RvD1 undergoes local metabolic inactivation in vivo [21] as does RvE1 [96, 97] , modifying their respective metabolic sites of inactivation within each molecule was undertaken to prepare stable mimetics. 17-(R/S)-methyl RvD1, 18-p-fluorophenoxy-17-epiRvD1, and RvE1 analogs were prepared by total organic synthesis [21, 96, 97] . In work in progress, both RvD1 and related analogs sharply reduced PMN and MPO levels in tissues. The RvE1 analog, 19-p-fluorophenoxy-RvE1 at 100ng to 1 μg/mouse significantly reduced leukocyte infiltration while native RvE1 was inactive in this system. This differs from topical application, e.g. on the eye, where RvE1 is potent [27, 98] . Mouse lung enzymatically converts RvE1 to inactive 18-oxo-RvE1 [96, 97] . The 19-p-fluorophenoxy RvE1 analog prevents rapid inactivation and displays potent protective actions [27] . Thus, by reducing Rv metabolic inactivation beneficial SPM actions can be sustained.
Evidence for pro-resolving receptors-Since RvD1 limits PMN infiltration, reduces human PMN transendothelial migration [2, 21] and has pro-resolving actions enhancing MΦ phagocytosis [99] , we prepared synthetic [ 3 H]-RvD1 [Fig (1B) ] to address specific RvD1 binding and recognition.
RvD1 and RvE1 do not activate nuclear receptors-Because some nuclear receptors may evoke anti-inflammatory responses [100] , we determined whether Rvs interact with specific nuclear receptors. To this end, HEK-293 cells were cotransfected with constructs of ligand binding domains for a panel of nuclear receptors linked to Gal4 DNA binding domain, along with a Gal4-responsive luciferase reporter. At anti-inflammatory doses [101] neither RvE1 nor RvD1 [1-100nM] directly activate PPAR-α, γ, and δ, or retinoid X receptor α (RXR) compared to known nuclear receptor agonists [102] .
RvD1 regulates actin polymerization: PTX sensitivity-We tested whether RvD1 regulates actin polymerization, a key event in migration [103] . Human PMN incubated with RvD1 (10 nM) resulted in a decrease in actin polymerization. To assess whether GPCRs are involved in RvD1 signaling, PMN were treated with either pertussis toxin (PTX), or activated cholera toxin (CT). PTX diminished RvD1-dependent reduction in actin polymerization, whereas incubation with activated CT did not. These suggest RvD1 acts via a PTX-sensitive GPCR. Also, RvD1 (10 nM) significantly blocked actin reorganization and CD11b cell surface expression stimulated by LTB 4 [10 nM] . With human PMN, RvD1 did not stimulate intracellular Ca 2+ nor activate cAMP suggesting that RvD1 signaling does not activate classic second messengers.
[ 3 H]-RvD1 specific binding-We next determined whether human phagocytes display specific RvD1 binding sites. To this end, tritium-labeled RvD1 ([ 3 H]-RvD1) was prepared by catalytic hydrogenation of synthetic [13, 14] -acetylenic RvD1-methyl ester (ME). Following catalytic hydrogenation, 3 H-labeled RvD1 co-eluted with authentic RvD1-ME beneath a single HPLC peak and gave characteristic UV absorbance [2, 21] . [ 3 H]-RvD1-ME was saponified to obtain the corresponding carboxylic acid, [13, 14] -[ 3 H] RvD1 and isolated immediately before each binding experiment. Representative saturation curves and Scatchard analysis are shown in Fig. (5A) . These indicate that [ 3 H]-RvD1 specifically binds to human PMN with high affinity K d = 0.17 nM ± 0.06 nM.
Competition binding was performed with RvD1, LXA 4 , and the annexin 1-derived peptide Ac2-12, an anti-inflammatory peptide ligand that binds to ALX [104] . RvD1 displaced [ 3 H]-RvD1 binding to cells, defining 100% specific binding Fig. (5B) . This specific binding was partially displaced ~ 60 % by LXA 4 while peptide Ac 2-12 did not compete Fig. (5B) . In parallel, [ 3 H]-RvD1 gave specific binding with human monocytes [102] . These results demonstrated RvD1 high affinity and specific binding with human phagocytes.
Screening for RvD1 receptor candidates-Since the handling of [ 3 H]-RvD1 is costly and not without difficulties but required, we also sought functional screening systems that do not rely on radiolabel. To this end, since RvD1 counters the actions of TNF-α [2], we employed for initial screening a luciferase-based reporter system we constructed earlier for identification of RvE1 receptors [18] . This system utilized a luciferase-based reporter that measures NF-κB activated by TNF-α [102] . Human cDNA sequences of phylogenetically related GPCR were cloned into pcDNA3 vector and then co-transfected into HeLa cells together with a reporter vector consisting of NF-κB promoter sequence linked to the luciferase gene. Among these human GPCRs, RvD1 significantly reduced TNF-α stimulated NF-κB activity only in cells overexpressing ALX and the orphan GPR32. In contrast, cells transfected with other sequence-related GPCRs including BLT1, BLT2, GPR-1, FPR, and ChemR23 [102] did not respond to RvD1. These panels were screened because they are expressed on human leukocytes and appear to be functionally related for cell motility [105] .
RvD1 directly acts at Human Orphan GPR32 and ALX-To monitor RvD1 receptor-ligand interactions, next we used a new GPCR-β-arrestin coupled system that is not signaling pathway dependent Fig. (6A) [106] because RvD1 does not simply mobilize Ca 2+ [102] . Incubation of GPR32-β-arrestin cells with RvD1 gave dose-dependent increases for interactions of β-arrestin and the receptor EC 50 ~ 8.8 × 10 −12 M. In parallel, LXA 4 also gave dose-dependent increases in the activation of GPR32 (EC 50 ~3.4 × 10 −11 M) Fig. (6B) . These findings, namely the K d and EC 50 values, are within the pg to ng range of RvD1 produced in vivo [107] and indicate that RvD1 and LXA 4 each directly activated GPR32. Recently, Amgen reported nitrosylated pyrazolone derivatives with agonistic actions on ALX receptor. The agonist denoted compound 43 is anti-inflammatory, potently reduces PMN migration and markedly inhibits mouse ear inflammation [70] . These results confirm our original identification of ALX-LXA 4 axis in inflammation using a separate medical chemistry approach [65] .
As an ALX anti-inflammatory agonist in vivo, we prepared synthetic compound 43 as in ref. [70] and tested it with our β-arrestin cells stably expressing GPR32. Compound 43 also activated GPR32, EC 50 = 2.25 × 10 −12 M, Fig. (6B) . In contrast, side-by-side comparisons indicated that RvD1 did not interact with ChemR23 compared to its lipid mediator ligand RvE1 [18] , EC 50 ~ 1.3 × 10 −11 M. These findings demonstrate high selectivity of these SPM for specific GPCR. RvD1 directly activated ALX with an affinity EC 50 ~ 1.2 × 10 −12 M. This was comparable to the activation of ALX by LXA 4 EC 50 ~ 1.1 × 10 −12 M Fig. (6C) . A receptor antagonist tert-butoxycarbonyl (t-Boc) peptide [108] blocked activation by both RvD1 and LXA 4 (IC 50 ~ 10 −5 M). Again, using compound 43 with ALX stable β arrestin cells gave a dose-dependent activation with an EC 50 of ~2.1 × 10 −12 M Fig. (6C) . For comparison, compound 43 was unable to activate β-arrestin system stably expressing ADP receptor P2Y12, indicating selectivity of ligand GPCR interactions. These results suggest that RvD1 interacts with both ALX and GPR32.
Overexpression of GPR32 and ALX in human MΦ enhances RvD1-stimulated phagocytosis-Since complete resolution requires phagocytosis and clearance of apoptotic PMN by MΦ from the inflammatory milieu, which is enhanced by resolvins [3] , we tested if RvD1 enhances human MΦ phagocytic activity. Human MΦ exposed to RvD1 enhanced their ability to ingest either zymosan or apoptotic human PMN in a dosedependent manner. RvD1 activity peaked at 0.1-1.0 nM and proved time-dependent [102] . Next, we transiently transfected human MΦ with expression vectors for RvD1 candidate receptors, i.e. human ALX or GPR32. RvD1 showed an increase in phagocytosis of zymosan in MΦ transfected with mock further increased in MΦ overexpressing either GPR32 or ALX [102] . Together, these results provide evidence for stereoselective specific binding of NPD1/PD1 with recognition sites on retinal pigment epithelial cells as well as human neutrophils. Moreover, they suggest the presence of specific receptors for this novel mediator in both the immune and visual systems [109] .
Summation
The acute inflammatory response is a self-limited protective mechanism. In response to injury or infection, excessive or uncontrolled inflammatory responses can lead to chronic disorders. Neutrophil-derived pro-inflammatory mediators, including leukotrienes and prostaglandins, are produced from arachidonic acid and are made in the initial phase of contained acute inflammatory responses that they can amplify. Within contained inflammatory exudates, we found that neutrophils can change phenotypes with time to generate protective mediators, derived from essential polyunsaturated fatty acids, to promote resolution. There is an active catabasis to return tissues to a homeostatic health state from the inflammatory battle [25] . These protective mediators include the arachidonic acidderived lipoxins as well as omega-3 EPA-derived resolvin E-series, DHA-derived resolvin-D series, protectins and maresins. These findings provide evidence that the resolution of acute inflammation is not a passive burning out of chemotactic signals, but rather an active, regulated process that orchestrates the clearance of inflammatory exudates. The endogenous production of pro-resolving lipid mediators, such as lipoxins, protectins and resolvins, as well as their administration in vivo, can accelerate the resolution of acute inflammation and the return to tissue homeostasis. The receptors for proresolving mediators and their signaling mechanisms in resolution can open new directions to treat inflammation-associated diseases. Identification of RvE1 receptor. (A) Functional screening for RvE1 receptors. HEK293 cells cotransfected with pNF-κB-luciferase and pcDNA3-GPCRs were exposed to RvE1 (10 nM) and TNF-α (inset) Phylogenetic tree representing amino acid sequence similarities between the human LXA 4 receptor (ALX), leukotriene B4 receptor (BLT1) and related GPCRs. (B) Receptor dependence. RvE1 inhibits luciferase activity in a concentration-dependent manner on cells transfected with ChemR23 but not mock transfected cells. (C) Ligand specificity. Cells transfected with pcDNA3-ChemR23 were exposed to 100 nM of each compound. RvE1 showed ~60%, while EPA and 18-HEPE do not have inhibition of NF-κB luciferase activity, (A) Tissue distribution of human ChemR23 determined by dot blot hybridization (B) Mechanisms of action for RvE1. In a ChemR3-dependent manner, RvE1 activates MAPK in monocytes, rS6 phosphorylation in macrophages, and reduces IL-12 production and migration in dendritic cells. RvE1 also induces expression of an anti-adhesive molecule CD55 on the apical surface of mucosal epithelium, promoting clearance of PMN across mucosal surface. In addition, RvE1 directly interact with BLT1 on human PMN, inhibiting calcium mobilization, NF-κB activation in vitro and PMN infiltration in vivo. Therefore RvE1 gave multi-level and cell-type specific actions, serving as an agonist for ChemR23 on mononuclear and dendritic cells as well as an antagonist for BLT1 signals on PMN. (A) Ligand-dependent receptor activation for monitoring receptor ligand interactions. This system is engineered by stably co-expressing the target GPCR (ALX or GPR32) tagged with the β-gal Pro-Link peptide with β-arrestin linked to the β-gal EA fragment. In the presence of ligand, activated GPCR interacts with β-arrestin, bringing to proximity the EA and ProLink fragments, forming a functional enzyme, whose activity can be measured by adding the substrate and generating a chemiluminescent signal. (B) Dose response activation curves of LXA 4 
